Precision medicine

December 20, 2022

From the Co-Chairs, December 2022

Reflections on NCI-MATCH and its successor trials; research results in leukemia and breast cancer; and grant renewal preparations
December 20, 2022

Trial Spotlight: Robert Ferris on the EA3132 Trial for Patients with Head and Neck Cancer

This phase 2 study is examining whether the addition of cisplatin to PORT will provide a survival benefit to certain patients with stage 3/4 squamous cell carcinoma of the head and neck
October 13, 2022

Trial Results: ECOG-ACRIN Research Round-Up

Summaries of recently published ECOG-ACRIN research results
August 16, 2022

NCI-MATCH precision medicine trial leads to FDA drug approval for BRAF V600E-mutated tumors

Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation
August 16, 2022

Trial Spotlight: Neha Vapiwala on the EA8191/INDICATE Study for Prostate Cancer

This phase III study is using PET/CT imaging to guide treatment for patients with post-prostatectomy biochemical recurrence
April 15, 2022

From the Co-Chairs, April 2022

Congress creates a new health care research agency; NCI-MATCH continues to offer treatment options; ECOG-ACRIN plans for first in-person Group Meeting since 2019
April 15, 2022

Now Enrolling: ECOG-ACRIN Opens a New NCI-MATCH Treatment Arm for dMMR and LAG-3-Positive Cancers as it Continues to Locate Patients with BRAF Mutations

The ground-breaking NCI-MATCH precision medicine cancer trial continues to offer treatment opportunities for adult patients with relapsed, refractory cancers. Lead investigators Nilo Azad, MD, and April Salama, MD, discuss Arms Z1M and H.
April 15, 2022

NCI-MATCH: The Blueprint for Future Precision Medicine Trials

In an enormous undertaking, ECOG-ACRIN and the NCI have built the knowledge base and infrastructure for future precision medicine trials. The new Genomics Subcommittee is offering expertise moving forward.
February 24, 2022

Trial Results: Copanlisib in Patients with PIK3CA-Mutated Tumors

The first published results of a platform trial of PIK3CA mutations across multiple tumor types appear in the Journal of Clinical Oncology. The data are from the NCI-MATCH precision medicine trial.
December 22, 2021

From the Co-Chairs, December 2021

The co-chairs reflect on key 2021 accomplishments, and share their thanks and best wishes for a happy New Year
December 22, 2021

ECOG-ACRIN Establishes Genomics Subcommittee

The purpose of this new subcommittee, led by Kristen Spencer, DO, MPH, is to develop molecularly-informed concepts—particularly combination concepts
September 30, 2021

NCI-MATCH Eliminates the Need for a Formal Referral Letter from the Laboratories

Removing one of several steps will help speed the process for identifying patients who may be eligible to enroll for treatment in NCI-MATCH